Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071388 | 1.00 | TDP1 (0.36) | TDP1IL1BSMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL195122 | 1.00 | TDP1 (0.36) | TDP1IL1BSMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL10249353 | 0.87 | IL1B (0.38) | TDP1IL1BSMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL10266156 | 0.87 | IL1B (0.38) | TDP1IL1BSMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL12209188 | 0.79 | KMT2A (0.35) | TDP1SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL15062707 | 0.78 | IL1B (0.35) | IL1BPIM1PIM2SRD5A1KAT2B | |
| SCHEMBL20838962 | 0.77 | JAK3 (0.40) | PIM1PIM2MEN1KMT2A | |
| SCHEMBL20851937 | 0.77 | JAK3 (0.40) | PIM1PIM2MEN1KMT2A | |
| SCHEMBL20838977 | 0.77 | JAK3 (0.40) | PIM1PIM2MEN1KMT2A | |
| SCHEMBL558118 | 0.76 | IL1B (0.35) | IL1BPIM1PIM2SRD5A1KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9161927-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-20 | — | — | US | disclosed |
| US-9115142-B2 | Heterocycle-substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-9090626-B2 | Piperazino-dihydrothienopyrimidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140350035-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-8877758-B2 | Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8759326-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8754073-B2 | Substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-20140107103-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-17 | — | — | US | disclosed |
| US-20140031343-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | disclosed |
| US-8637519-B2 | Heterocycle-substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-20130274264-A1 | PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-17 | — | — | US | disclosed |
| US-20130237527-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| US-20130225609-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-8486948-B2 | Piperazinodihydrothienopyrimidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20120035143-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20120028932-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20110046096-A1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110028441-A1 | NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350035-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS | PTGER4, PTGER1, PDE4A | TDP1 2837/4885IL1B 1918/4885SMN1; SMN2 4444/4885 |
| US-20110046096-A1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | DPYD, PRDX5, PRDX1 | TDP1 1968/4885IL1B 1029/4885SMN1; SMN2 652/4885 |
| US-20140031343-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | PTGER4, PDE4A, PDE12 | TDP1 1720/4885IL1B 1288/4885SMN1; SMN2 2295/4885 |
| US-20130274264-A1 | PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | PDE4A, PDE12, PDE4B | TDP1 141/4885IL1B 2541/4885SMN1; SMN2 1230/4885 |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | SULT2A1, DPYD, HRH2 | TDP1 2237/4885IL1B 1010/4885SMN1; SMN2 486/4885 |
| US-20140107103-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | HRH2, HRH1, HRH4 | TDP1 2672/4885IL1B 1051/4885SMN1; SMN2 699/4885 |
| US-20130225609-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | PTGER4, PTGER1, PDE4A | TDP1 2837/4885IL1B 1918/4885SMN1; SMN2 4444/4885 |
| US-20120035143-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | PDE4A, PDE12, PDE3B | TDP1 1066/4885IL1B 1061/4885SMN1; SMN2 2246/4885 |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | DPYD, P2RX1, P2RX5 | TDP1 1008/4885IL1B 792/4885SMN1; SMN2 338/4885 |
| US-20130237527-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | PTGER4, PTGER1, PTGER3 | TDP1 3722/4885IL1B 1910/4885SMN1; SMN2 4366/4885 |
| US-20110028441-A1 | NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | DPYD, DPM1, DDX41 | TDP1 499/4885IL1B 478/4885SMN1; SMN2 375/4885 |
| US-20120028932-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | PTGER4, PDE4A, PDE3B | TDP1 2175/4885IL1B 1313/4885SMN1; SMN2 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.